Author

Johan Georg Visser

University of OsloORCID 0000-0002-4614-4494Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Brian C. GilmouriD· 2 shared Pawel P. BorowicziD· 2 shared Spurkland AnneiD· 2 shared Aliki Popidou· 1 shared Alvaro Köhn‐LuqueiD· 1 shared Andreas LossiusiD· 1 shared Gustavo Antonio de SouzaiD· 1 shared Hanna ChaniD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Brian C. GilmourORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintFeb 5, 2026

Intrinsically disordered insert from SH2D2A rewires CD19 CAR signaling via Tyr290

Pawel P. Borowicz, Brian C. Gilmour, Hanna Chan…·Spurkland Anne

This study identifies a specific tyrosine residue in an intrinsically disordered SH2D2A sequence that rewires CD19 CAR signaling and surface expression.

DOI 10.64898/2026.02.03.703491

humanproteomics

𝕏 PostBluesky

BioinformaticsbioRxivPreprintJan 13, 2025

SH2D2A is an indicator of favourable prognosis in bladder cancer and is enriched in Treg cells

Brian C. Gilmour, Johan Georg Visser, Alvaro Köhn‐Luque…·Anne Spurkland

The paper identifies SH2D2A as a favourable prognosis marker in bladder cancer, enriched in Treg cells, and suggests its role in immunotherapy targets.

DOI 10.1101/2025.01.13.632739

humanbulk RNA-seq

𝕏 PostBluesky